CPTCF (Cytophage Technologies) Current Accrued Expense: $0.08 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CPTCF Cytophage Technologies Ltd CPTCF
18 GF Score
Price $0.21
! 1 Warning Sign
View Full Analysis

What is Cytophage Technologies Current Accrued Expense?

Cytophage Technologies CPTCF 18 Current Accrued Expense is $0.08 Mil as of Dec. 2025. GuruFocus rates CPTCF with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

Cytophage Technologies's Current Accrued Expense for the quarter that ended in Dec. 2025 was $0.08 Mil.

Cytophage Technologies's quarterly Current Accrued Expense declined from Jun. 2025 ($0.16 Mil) to Sep. 2025 ($0.15 Mil) and declined from Sep. 2025 ($0.15 Mil) to Dec. 2025 ($0.08 Mil).

Cytophage Technologies's annual Current Accrued Expense declined from Dec. 2023 ($0.31 Mil) to Dec. 2024 ($0.18 Mil) and declined from Dec. 2024 ($0.18 Mil) to Dec. 2025 ($0.08 Mil).

Cytophage Technologies Current Accrued Expense Related Terms

Cytophage Technologies Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Cytophage Technologies's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytophage Technologies Current Accrued Expense Chart

Cytophage Technologies Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
0.01 0.01 0.31 0.18 0.08

Cytophage Technologies Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.15 0.16 0.15 0.08
CPTCF
18GF Score
Cytophage Technologies Ltd CPTCF
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cytophage Technologies Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.08 Mil mean?
Cytophage Technologies (CPTCF) has a Current Accrued Expense of $0.08 Mil as of Dec. 2025. Current Accrued Expense records the total amount of accrued expenses. View historical data on Cytophage Technologies and its competitors.
Is Cytophage Technologies' Current Accrued Expense too high?
Cytophage Technologies' current Current Accrued Expense is $0.08 Mil. Overall, Cytophage Technologies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Cytophage Technologies' Current Accrued Expense compare to VRTX and REGN?
Cytophage Technologies' Current Accrued Expense of $0.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Cytophage Technologies and its competitors. Cytophage Technologies's current Current Accrued Expense is $0.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytophage Technologies stock overvalued right now?
Cytophage Technologies (CPTCF) has a current Current Accrued Expense of $0.08 Mil. The current Current Accrued Expense is $0.08 Mil. Cytophage Technologies' overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Cytophage Technologies (CPTCF), the current Current Accrued Expense is $0.08 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cytophage Technologies Business Description

Other Exchanges CYTO.H:Canada
Address 400 Fort Whyte Way, Suite 200A, Oak Bluff, MB, CAN, R4G 0B1
Cytophage Technologies Ltd is a Canadian biotechnology company engaged in the development of bacteriophages using molecular genetics and synthetic biology techniques. The company focuses on developing bacteriophage-based solutions to address bacterial challenges affecting animal health, human health, and food security, including antibiotic-resistant bacterial strains.
18GF Score

Get the complete analysis for CPTCF

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price